🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT06710938
Recruiting Not applicable

Thoracoabdominal Artery Stent Graft System Exploratory Study

NCT06710938 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2025-07-24
Last updated
2026-05-26

Condition(s) studied

Thoracoabdominal Aortic Aneurysms

Investigational drug(s) / intervention(s)

The system includes the G-Branch™ thoracoabdominal aortic stent graft system, the peripheral vascular stent graft system, and the aortic extension stent graft system

The system includes the G-Branch™ thoracoabdominal aortic stent graft system, the peripheral vascular stent graft system, and the aortic extension stent graft system: The thoracoabdominal artery stent graft system is a mixed branch design with two inner branches for the visceral arteries and two outer branches for the bilateral renal arteries.

Study summary

This study is designed as a single-center, prospective, single-arm, open-label, exploratory study. The objective is to evaluate the feasibility of Thoracoabdominal Artery Stent Graft System for endovascular treatment of Thoracoabdominal aortic aneurysms (TAAA).

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age: 18 to 80 years old; 2. Patients diagnosed with a Thoracoabdominal aortic aneurysm (based on the modified Crawford classification and European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms), and should meet at least ONE of the following conditions: 1. Maximum diameter of TAAA is \>50 mm; 2. TAAA diameter increases by more than 5 mm in the past 6 months or by more than 10 mm in the past 1 year; 3. Definite symptoms associated with TAAA, such as abdominal pain and back pain. 3. Anatomical Criteria 1. Proximal landing zone (aorta or implanted graft): the diameter ranges from 17 to 36 mm, and length should be ≥25 mm; 2. Distal landing zone (aorta or implanted graft): If distal landing zone is in iliac artery, distal landing zone diameter ranges from 7 to 25 mm, and length should be ≥15 mm; If the distal landing zone is in the abdominal aorta, distal landing zone diameter ranges from 12 to 36 mm, and length should be ≥20 mm. 3. Visceral branch landing zone: the diameter ranges from 6 to 13 mm, and the length should be ≥15 mm; 4. Renal artery landing zone: the diameter ranges from 4.5 to 9 mm, and the length should be ≥15 mm; 5. Appropriate iliac, femoral, and upper limb arterial access. 4. Patients who understand the purpose of the study, volunteer to participate and sign the informed consent form, and are willing to complete follow-up as required by the protocol; 5. Patients do not want to or cannot wait for the approved alternative Exclusion Criteria: Exclusion Criteria (not eligible if any of the criteria is met): 1. Patients with ruptured thoracoabdominal aortic aneurysms in unstable hemodynamic condition; 2. Patients with thoracoabdominal aortic dissection; 3. Patients with infected or mycotic thoracoabdominal aortic aneurysms; 4. Patients with systemic or local infections that may increase the risk of endovascular graft infection; 5. Patients with occluded superior mesenteric artery, celiac trunk artery, or renal artery; 6. Patients requiring simultaneous coverage or embolization of bilateral internal iliac arteries; 7. Patients with severe stenosis, calcification or mural thrombus at stent-graft landing zone, and this situation leads to difficulty in adhering the covered stent or affecting the patency of the stent; 8. Patients with a history of acute coronary syndrome within the recent 6 months; Acute coronary syndrome refers to acute cardiac ischemic syndrome caused by rupture or erosion of unstable atherosclerotic plaques in the coronary artery and fresh thrombosis, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina pectoris. 9. Patients with transient ischemic attack (TIA) or ischemic/hemorrhagic stroke within the recent 3 months; 10. Patients with abnormal liver and kidney function before operation \[alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 times the upper limit of normal value; Serum creatinine (Cr) \>150umol/L\]; 11. Patients with severe pulmonary insufficiency who cannot tolerate general anesthesia;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Asklepios Klinik Nord Heidberg Hamburg Germany Recruiting

More Lifetech Scientific (Shenzhen) Co., Ltd. trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06710938 on ClinicalTrials.gov ↗ ← All trials in Germany